611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Mental Disorders
Resources
Basic InformationLookupsLatest News
Ketamine Beneficial for Certain Patients With Mood DisordersPatients Reluctant to Comply With Drug-Only Psychiatric TreatmentPatients Often Reject Drug-Only Psychiatric TreatmentStudy Links Psychiatric Disorders to Stroke RiskAnxiety, Depression May Up Mortality Risk for Some CancersMental Health May Affect Chances Against CancerObamacare Covered More People With Mental Illness, AddictionsMany With Mental Illness Miss Out on HIV TestsPlastic Surgeons Often Miss Patients' Mental DisordersMortality Risk in T2DM Increased With Depression and/or AnxietyMost Smokers With Mental Illness Want to Kick the HabitRate of Psychiatric Drug Use About 16 Percent in U.S. Adults1 in 6 U.S. Adults Takes a Psychiatric Drug: StudyFor People With Mental Health Woes, Pets Can Be InvaluableHealth Tip: Thinking About Psychological Therapy?Heart Rate, BP in Male Teens Tied to Later Risk for Psych DisordersU.S. Psychiatric Patients Face Long Waits in ERsAre Some Blood Pressure Meds Linked to Depression, Bipolar Risk?Study Links Pot Use to Relapse in Psychosis PatientsInternet Addiction May Be Red Flag for Other Mental Health Issues: StudyPsychiatric Patients Face Longer Waits in ERParents' Psychiatric Issues May Adversely Affect Some ChildrenAntipsychotic Meds Pose Little Danger to Fetus, Study FindsInfertility Patients' Mental Health Problems Often UnaddressedStudy of Teen Brains Offers Clues to Timing of Mental IllnessHealth Tip: Take Steps to Stay Mentally HealthyAre 'Workaholics' Prone to OCD, Anxiety?Mentally Ill Still Gain Illegal Possession of Guns, Study ShowsMental Disorders Were Most Costly in U.S. in 2013For New Antipsychotic Users, Dose, Duration Impact MortalityNo Link Between Anti-Smoking Drugs, Mental Health Issues: StudyU.S. Soldier in Custody Following Slaying of 5 Americans in Iraq
Questions and AnswersLinksBook Reviews
Related Topics

Anxiety Disorders
Bipolar Disorder
Depression: Depression & Related Conditions
Schizophrenia
Eating Disorders

No Link Between Anti-Smoking Drugs, Mental Health Issues: Study

HealthDay News
by -- Robert Preidt
Updated: Apr 22nd 2016

new article illustration

FRIDAY, April 22, 2016 (HealthDay News) -- The anti-smoking drugs Chantix (varenicline) and Wellbutrin (bupropion) don't appear to raise the risk of serious mental health disorders such as depression, anxiety and suicidal thoughts, a new study suggests.

"Clinical guidelines recommend that the most effective way to give up smoking is smoking cessation medication and counseling. However, smokers do not use these services enough, in part due to concerns that the medications may not be safe," said lead author Dr. Robert Anthenelli, professor of psychiatry at University of California, San Diego.

The new study, published April 22 in The Lancet, should help ease those concerns for patients, the researchers said.

The study was requested by the U.S. Food and Drug Administration due to concerns about the safety of the drugs used to help people quit smoking. Funding was provided by drug makers Pfizer (which makes Chantix) and GlaxoSmithKline (maker of Wellbutrin).

The research included more than 8,000 people between the ages of 18 and 75. They smoked an average of more than 10 cigarettes a day and wanted to quit smoking. Half had a previous or current psychiatric condition, such as a mood, anxiety, psychotic or borderline personality disorder, while about half of those participants were taking medications for their conditions.

The participants were randomly assigned to one of four possible groups: to take either Chantix or Wellbutrin, to use nicotine patches or to take a placebo.

They were assessed for moderate-to-severe mental health problems such as agitation, aggression, panic, anxiety, depression and suicidal thoughts during up to three months of treatment and at follow-up (up to six months).

Among those with no psychiatric disorders, there was no significant increase in the incidence of mental health problems in the four groups. While more mental health problems occurred among participants with psychiatric disorders, the rates were similar for all four groups, the study found.

The researchers also examined quit rates and found that varenicline was the most effective. At follow-up, overall quit rates were: 22 percent, Chantix; 16 percent, Wellbutrin; 16 percent, nicotine patches; and 9 percent, placebo.

Quit rates were slightly lower for those with a psychiatric disorder, the study said.

Anthenelli said the findings from this study and previous ones make it unlikely that these drugs increase the risk of moderate-to-severe mental health side effects in smokers without psychiatric disorders.

The study results "show that neuropsychiatric adverse events occurring during smoking cessation are independent of the medication used," addiction expert Laurie Zawertailo wrote in an accompanying editorial.

"Clinicians should be comfortable prescribing the smoking cessation medication they feel would be most effective for their patient and should not worry about a specific medication increasing the risk of neuropsychiatric side effects," said Zawertailo, an assistant professor in the department of Pharmacology and Toxicology at the University of Toronto.

She added that patients who are trying to quit need to know that severe changes in their mood can occur.

"Clinicians should monitor all of their patients, especially those with a current or past psychiatric illness, for these changes," Zawertailo said. "This monitoring could be added to the behavioral counseling that clinicians should be providing to patients who are trying to quit smoking."

Two experts in helping smokers quit said the findings are valuable for patients.

"In my experience there has been reluctance among many practitioners to prescribe varenicline and/or bupropion for their tobacco-dependent patients, due to concerns about potential neuropsychiatric adverse events," said Patricia Folan. She directs the Center for Tobacco Control at Northwell Health in Great Neck, N.Y.

She said many smokers also look for information on quit-smoking aids on the internet, and "frequently decide to avoid these medications because of the reported side effects -- resulting in their continued smoking.

"Demonstrating the safety and efficacy of these cessation treatment options for tobacco users will most likely lead to additional quit attempts and quit success," Folan believes.

Dr. Len Horovitz is a pulmonary specialist at Lenox Hill Hospital in New York City. He agreed that, based on the new findings, "medication-assisted smoking cessation is safe and freer from side effects than patients -- and doctors -- may fear."

More information

The American Cancer Society offers a guide to quitting smoking.